Psychemedics (PMD) Stock
Company Profile
Price: $2.31
Market Cap: $13.45M
Exchange: NASDAQ
CEO: Mr. Brian Hullinger
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: -0.00B
Headquarters: Acton, MA
Website: Psychemedics
Business Summary
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
Psychemedics Chart
Psychemedics News
Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing
DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report.
-
globenewswire.com
2024-09-26
Psychemedics Corporation Reports Second Quarter 2024 Financial Results
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024.
-
globenewswire.com
2024-08-13
Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock
DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has recommended, and the Board has approved, a plan to cease the registration of the Company's common stock under the federal securities laws following the completion of a proposed reverse stock split and to delist its shares of common stock from trading on the Nasdaq Capital Market. It is expected that this plan would be effectuated in the fall of 2024, assuming the approval of Psychemedics' stockholders at the Company's 2024 Annual Meeting of Stockholders, among other things, as described below.
-
globenewswire.com
2024-08-12
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023.
-
globenewswire.com
2024-06-21
Psychemedics Corporation Reports First Quarter 2024 Financial Results
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024.
-
globenewswire.com
2024-05-14
Psychemedics Corporation Reports 2023 Financial Results
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023.
-
globenewswire.com
2024-03-28
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider
Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics' commitment to excellence and innovation in the field of employee health testing.
-
globenewswire.com
2024-03-21
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing.
-
globenewswire.com
2024-01-02
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance.
-
globenewswire.com
2023-11-27
Psychemedics Earnings
This section highlight's Psychemedics's earnings, including earnings call transcripts, earnings surprises, and key dates.
Psychemedics Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Psychemedics Earnings Dates
When is the next earnings date for PMD?
Date: 2024-11-07Status: Unconfirmed
Time of Day: Before Market
Estimated EPS: $-
When was the last earnings date for PMD?
Date: 2024-08-13Fiscal Date Ending: 2024-06-30
EPS: $-0.14
Estimated EPS: $-
Revenue: $4.73M
Estimated Revenue: $-
Upcoming PMD Earnings
| Date | Estimated EPS | Time of Day | Status |
|---|---|---|---|
| 2024-11-07 | N/A | Before Market | Unconfirmed |
| 2025-03-26 | N/A | -- | Unconfirmed |
| 2025-05-12 | N/A | -- | Unconfirmed |
| 2025-08-11 | N/A | -- | Unconfirmed |
Financial Statements
This section provides financial statements for Psychemedicsincluding income statements, balance sheets, and cash flow statements, both annually and quarterly.
Annual Income Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Revenue | $37.68M | $21.36M | $24.91M | $25.24M | $22.10M |
| Cost of Revenue | $21.23M | $16.47M | $14.64M | $15.95M | $13.69M |
| Gross Profit | $16.44M | $4.89M | $10.26M | $9.29M | $8.41M |
| Gross Profit Ratio | 43.64% | 22.87% | 41.21% | 36.81% | 38.07% |
| Research and Development Expenses | $1.57M | $1.28M | $1.13M | $1.33M | $1.14M |
| General and Administrative Expenses | $7.22M | $6.09M | $6.13M | $5.86M | $7.19M |
| Selling and Marketing Expenses | $4.66M | $3.58M | $2.80M | $3.19M | $3.00M |
| Selling General and Administrative Expenses | $11.88M | $9.67M | $8.93M | $9.05M | $10.19M |
| Other Expenses | $58.00K | $-140.00K | $-1.03M | $43.00K | $-10.00K |
| Operating Expenses | $13.45M | $10.95M | $10.05M | $10.37M | $11.33M |
| Cost and Expenses | $34.68M | $27.43M | $24.70M | $26.32M | $25.02M |
| Interest Income | $134.00K | $75.00K | $49.00K | $32.00K | $- |
| Interest Expense | $59.00K | $75.00K | $49.00K | $-43.00K | $- |
| Depreciation and Amortization | $2.91M | $3.63M | $3.69M | $3.32M | $2.67M |
| EBITDA | $3.00M | $-6.07M | $209.00K | $-1.08M | $-251.00K |
| EBITDA Ratio | 7.96% | -28.40% | 0.84% | -4.29% | -1.14% |
| Operating Income | $84.00K | $-6.07M | $-3.48M | $-1.08M | $-2.92M |
| Operating Income Ratio | 0.22% | -28.40% | -13.97% | -4.29% | -13.22% |
| Total Other Income Expenses Net | $2.97M | $-140.00K | $2.66M | $43.00K | $-517.00K |
| Income Before Tax | $3.06M | $-6.21M | $-821.00K | $-1.04M | $-3.44M |
| Income Before Tax Ratio | 8.11% | -29.05% | -3.30% | -4.12% | -15.56% |
| Income Tax Expense | $1.51M | $-2.35M | $-156.00K | $44.00K | $716.00K |
| Net Income | $1.54M | $-3.86M | $-665.00K | $-1.08M | $-4.15M |
| Net Income Ratio | 4.09% | -18.07% | -2.67% | -4.29% | -18.80% |
| EPS | $0.28 | $-0.70 | $-0.12 | $-0.19 | $-0.72 |
| EPS Diluted | $0.28 | $-0.70 | $-0.12 | $-0.19 | $-0.72 |
| Weighted Average Shares Outstanding | 5.51M | 5.52M | 5.55M | 5.63M | 5.74M |
| Weighted Average Shares Outstanding Diluted | 5.53M | 5.52M | 5.55M | 5.63M | 5.74M |
| SEC Filing | Source | Source | Source | Source | Source |
Quarterly Income Statement
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.85M | $8.71M | $7.54M | $3.31M | $5.17M | $5.33M | $5.71M | $6.09M | $6.67M | $6.44M | $6.51M | $6.51M | $6.52M | $5.70M | $5.86M | $5.54M | $5.70M | $5.00M | $5.36M | $4.73M |
| Cost of Revenue | $5.47M | $5.23M | $4.81M | $3.57M | $4.04M | $4.06M | $3.15M | $3.65M | $3.60M | $4.25M | $4.07M | $4.24M | $4.18M | $3.46M | $3.65M | $3.48M | $3.61M | $2.94M | $3.23M | $3.18M |
| Gross Profit | $4.38M | $3.48M | $2.73M | $-252.00K | $1.13M | $1.28M | $2.57M | $2.44M | $3.08M | $2.19M | $2.44M | $2.27M | $2.33M | $2.25M | $2.21M | $2.06M | $2.09M | $2.06M | $2.12M | $1.55M |
| Gross Profit Ratio | 44.48% | 39.99% | 36.19% | -7.60% | 21.90% | 23.94% | 44.95% | 40.02% | 46.08% | 33.95% | 37.51% | 34.90% | 35.79% | 39.37% | 37.63% | 37.19% | 36.66% | 41.18% | 39.61% | 32.83% |
| Research and Development Expenses | $393.00K | $354.00K | $331.00K | $345.00K | $305.00K | $299.00K | $280.00K | $293.00K | $244.00K | $313.00K | $318.00K | $357.00K | $328.00K | $323.00K | $298.00K | $286.00K | $275.00K | $285.00K | $209.00K | $189.00K |
| General and Administrative Expenses | $1.42M | $2.53M | $1.53M | $1.85M | $1.34M | $1.37M | $1.53M | $1.28M | $1.33M | $1.99M | $1.33M | $1.45M | $1.59M | $1.50M | $1.65M | $1.44M | $2.20M | $1.90M | $1.79M | $1.59M |
| Selling and Marketing Expenses | $1.24M | $1.20M | $1.11M | $856.00K | $896.00K | $719.00K | $642.00K | $656.00K | $652.00K | $849.00K | $806.00K | $813.00K | $791.00K | $781.00K | $789.00K | $746.00K | $723.00K | $740.00K | $692.00K | $671.00K |
| Selling General and Administrative Expenses | $2.65M | $3.74M | $2.64M | $2.71M | $2.24M | $2.09M | $2.17M | $1.94M | $1.98M | $2.84M | $2.13M | $2.26M | $2.38M | $2.28M | $2.44M | $2.19M | $2.92M | $2.64M | $2.48M | $2.26M |
| Other Expenses | $6.00K | $4.00K | $-73.00K | $-39.00K | $-17.00K | $-11.00K | $-14.00K | $- | $-31.00K | $-1.09M | $66.00K | $-9.00K | $-8.00K | $-6.00K | $-5.00K | $-5.00K | $- | $-1.00K | $-3.00K | $1.00K |
| Operating Expenses | $3.05M | $4.09M | $2.97M | $3.05M | $2.54M | $2.39M | $2.45M | $2.23M | $2.23M | $3.15M | $2.45M | $2.62M | $2.71M | $2.60M | $2.73M | $2.48M | $3.20M | $2.93M | $2.69M | $2.45M |
| Cost and Expenses | $8.52M | $9.32M | $7.78M | $6.62M | $6.58M | $6.44M | $5.60M | $5.88M | $5.82M | $7.40M | $6.52M | $6.86M | $6.89M | $6.06M | $6.39M | $5.95M | $6.81M | $5.87M | $5.92M | $5.63M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $32.00K | $5.00K | $5.00K | $- | $-10.00K | $- | $- |
| Interest Expense | $-6.00K | $-4.00K | $73.00K | $39.00K | $17.00K | $11.00K | $14.00K | $- | $-181.00K | $2.17M | $-66.00K | $9.00K | $8.00K | $6.00K | $-709.00K | $- | $- | $17.00K | $- | $- |
| Depreciation and Amortization | $718.00K | $695.00K | $874.00K | $907.00K | $927.00K | $918.00K | $911.00K | $912.00K | $1.01M | $859.00K | $860.00K | $867.00K | $827.00K | $762.00K | $714.00K | $696.00K | $685.00K | $575.00K | $551.00K | $664.00K |
| EBITDA | $1.33M | $-606.00K | $-242.00K | $-2.40M | $-1.41M | $-1.11M | $117.00K | $207.00K | $1.75M | $-965.00K | $850.00K | $-342.00K | $452.00K | $-356.00K | $-528.00K | $83.00K | $-1.11M | $-293.00K | $-16.00K | $-235.00K |
| EBITDA Ratio | 13.54% | -6.95% | -3.21% | -72.39% | -27.23% | -20.79% | 2.05% | 3.40% | 26.26% | -14.99% | 13.06% | -5.25% | 6.94% | -6.24% | -9.01% | 1.50% | -19.41% | -5.86% | -0.30% | -4.97% |
| Operating Income | $1.33M | $-606.00K | $-242.00K | $-3.31M | $-1.41M | $-1.11M | $117.00K | $207.00K | $850.00K | $-965.00K | $-10.00K | $-342.00K | $-375.00K | $-356.00K | $-528.00K | $-417.00K | $-1.11M | $-868.00K | $-567.00K | $-899.00K |
| Operating Income Ratio | 13.54% | -6.95% | -3.21% | -99.76% | -27.23% | -20.79% | 2.05% | 3.40% | 12.74% | -14.99% | -0.15% | -5.25% | -5.76% | -6.24% | -9.01% | -7.53% | -19.41% | -17.37% | -10.58% | -19.01% |
| Total Other Income Expenses Net | $6.00K | $4.00K | $-73.00K | $-39.00K | $-17.00K | $-11.00K | $-14.00K | $- | $75.00K | $-1.09M | $66.00K | $-9.00K | $-8.00K | $-6.00K | $-5.00K | $-505.00K | $- | $-8.00K | $-5.00K | $1.00K |
| Income Before Tax | $1.34M | $-602.00K | $-315.00K | $-3.35M | $-1.43M | $-1.12M | $103.00K | $207.00K | $925.00K | $-2.06M | $56.00K | $-351.00K | $-383.00K | $-362.00K | $-533.00K | $-922.00K | $-1.11M | $-876.00K | $-572.00K | $-898.00K |
| Income Before Tax Ratio | 13.60% | -6.91% | -4.18% | -100.94% | -27.56% | -20.99% | 1.80% | 3.40% | 13.86% | -31.96% | 0.86% | -5.39% | -5.88% | -6.35% | -9.10% | -16.65% | -19.41% | -17.53% | -10.68% | -18.99% |
| Income Tax Expense | $663.00K | $-72.00K | $-156.00K | $-1.29M | $-319.00K | $-577.00K | $20.00K | $73.00K | $186.00K | $-436.00K | $17.00K | $-13.00K | $-286.00K | $326.00K | $-149.00K | $-196.00K | $992.00K | $69.00K | $116.00K | $-71.00K |
| Net Income | $677.00K | $-530.00K | $-159.00K | $-2.05M | $-1.11M | $-543.00K | $83.00K | $134.00K | $739.00K | $-1.62M | $39.00K | $-338.00K | $-97.00K | $-688.00K | $-384.00K | $-726.00K | $-2.10M | $-945.00K | $-688.00K | $-827.00K |
| Net Income Ratio | 6.87% | -6.08% | -2.11% | -61.86% | -21.40% | -10.18% | 1.45% | 2.20% | 11.07% | -25.19% | 0.60% | -5.19% | -1.49% | -12.06% | -6.55% | -13.11% | -36.80% | -18.91% | -12.84% | -17.49% |
| EPS | $0.12 | $-0.10 | $-0.03 | $-0.37 | $-0.20 | $-0.10 | $0.01 | $0.02 | $0.13 | $-0.29 | $0.01 | $-0.06 | $-0.02 | $-0.12 | $-0.07 | $-0.13 | $-0.36 | $-0.16 | $-0.12 | $-0.14 |
| EPS Diluted | $0.12 | $-0.09 | $-0.03 | $-0.37 | $-0.20 | $-0.10 | $0.01 | $0.02 | $0.13 | $-0.29 | $0.01 | $-0.06 | $-0.02 | $-0.12 | $-0.07 | $-0.13 | $-0.36 | $-0.16 | $-0.12 | $-0.14 |
| Weighted Average Shares Outstanding | 5.52M | 5.52M | 5.30M | 5.52M | 5.53M | 5.53M | 5.54M | 5.54M | 5.54M | 5.59M | 5.59M | 5.61M | 5.64M | 5.73M | 5.68M | 5.71M | 5.75M | 5.81M | 5.81M | 5.82M |
| Weighted Average Shares Outstanding Diluted | 5.64M | 5.89M | 5.52M | 5.52M | 5.53M | 5.54M | 5.64M | 5.63M | 5.63M | 5.59M | 5.65M | 5.61M | 5.64M | 5.73M | 5.68M | 5.71M | 5.75M | 5.81M | 5.81M | 5.82M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $7.28M | $2.83M | $1.99M | $4.75M | $1.96M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $7.28M | $2.83M | $1.99M | $4.75M | $1.96M |
| Net Receivables | $3.78M | $5.85M | $6.79M | $4.08M | $3.71M |
| Inventory | $- | $- | $-0.00B | $- | $-0.00B |
| Other Current Assets | $1.79M | $914.00K | $1.50M | $1.14M | $1.14M |
| Total Current Assets | $12.85M | $9.60M | $10.29M | $9.96M | $6.80M |
| Property Plant Equipment Net | $13.74M | $13.52M | $10.24M | $7.25M | $4.89M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $1.84M | $2.63M | $160.00K | $691.00K | $944.00K |
| Other Non-Current Assets | $-901.00K | $-1.74M | $864.00K | $823.00K | $632.00K |
| Total Non-Current Assets | $14.68M | $14.40M | $11.27M | $8.77M | $6.46M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $27.53M | $24.00M | $21.55M | $18.73M | $13.27M |
| Account Payables | $617.00K | $577.00K | $994.00K | $448.00K | $752.00K |
| Short Term Debt | $1.64M | $1.56M | $1.65M | $1.33M | $1.35M |
| Tax Payables | $564.00K | $4.00K | $200.00K | $771.00K | $553.00K |
| Deferred Revenue | $- | $- | $- | $- | $553.00K |
| Other Current Liabilities | $3.58M | $1.80M | $3.19M | $3.94M | $2.05M |
| Total Current Liabilities | $5.83M | $3.94M | $5.83M | $5.72M | $4.71M |
| Long Term Debt | $4.33M | $7.34M | $3.48M | $2.24M | $945.00K |
| Deferred Revenue Non-Current | $1.95M | $3.44M | $-1.55M | $-1.19M | $- |
| Deferred Tax Liabilities Non-Current | $550.00K | $211.00K | $2.15M | $1.49M | $944.00K |
| Other Non-Current Liabilities | $-1.95M | $-3.44M | $-599.00K | $-305.00K | $- |
| Total Non-Current Liabilities | $4.88M | $7.55M | $3.48M | $2.24M | $1.89M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $10.71M | $11.49M | $9.31M | $7.96M | $6.60M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $31.00K | $31.00K | $31.00K | $32.00K | $32.00K |
| Retained Earnings | $-3.75M | $-8.61M | $-9.55M | $-11.82M | $-16.77M |
| Accumulated Other Comprehensive Income Loss | $-1.62M | $-1.63M | $-1.63M | $-1.63M | $-1.63M |
| Other Total Stockholders Equity | $22.17M | $22.72M | $23.40M | $24.19M | $25.05M |
| Total Stockholders Equity | $16.82M | $12.51M | $12.24M | $10.77M | $6.67M |
| Total Equity | $16.82M | $12.51M | $12.24M | $10.77M | $6.67M |
| Total Liabilities and Stockholders Equity | $27.53M | $24.00M | $21.55M | $18.73M | $13.27M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $27.53M | $24.00M | $21.55M | $18.73M | $13.27M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $5.97M | $8.90M | $5.13M | $3.57M | $2.30M |
| Net Debt | $-1.32M | $6.07M | $3.13M | $-1.18M | $334.00K |
Quarterly Balance Sheet
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $6.49M | $7.28M | $5.33M | $3.67M | $1.81M | $2.83M | $2.19M | $2.65M | $1.97M | $1.99M | $2.13M | $1.79M | $3.46M | $4.75M | $4.38M | $2.44M | $1.37M | $1.96M | $1.42M | $1.43M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $6.49M | $7.28M | $5.33M | $3.67M | $1.81M | $2.83M | $2.19M | $2.65M | $1.97M | $1.99M | $2.13M | $1.79M | $3.46M | $4.75M | $4.38M | $2.44M | $1.37M | $1.96M | $1.42M | $1.43M |
| Net Receivables | $5.17M | $3.78M | $3.56M | $4.59M | $5.72M | $5.85M | $6.54M | $6.51M | $6.95M | $6.79M | $7.37M | $7.39M | $5.76M | $4.08M | $4.07M | $4.01M | $4.98M | $3.71M | $3.90M | $3.07M |
| Inventory | $-0.00B | $- | $- | $-0.00B | $-0.00B | $- | $-0.00B | $- | $- | $-0.00B | $- | $-0.00B | $-0.00B | $- | $- | $-0.00B | $-0.00B | $-0.00B | $- | $- |
| Other Current Assets | $1.82M | $1.79M | $1.89M | $1.50M | $1.30M | $914.00K | $1.90M | $2.58M | $2.75M | $1.50M | $1.03M | $1.72M | $1.51M | $1.14M | $1.09M | $1.77M | $1.52M | $1.14M | $870.00K | $1.50M |
| Total Current Assets | $13.49M | $12.85M | $10.78M | $9.75M | $8.83M | $9.60M | $10.63M | $11.74M | $11.67M | $10.29M | $10.53M | $10.90M | $10.72M | $9.96M | $9.54M | $8.23M | $7.87M | $6.80M | $6.19M | $6.01M |
| Property Plant Equipment Net | $12.35M | $13.74M | $13.50M | $15.10M | $14.25M | $13.52M | $12.87M | $12.00M | $11.08M | $10.24M | $9.44M | $8.70M | $7.98M | $7.25M | $6.68M | $6.06M | $5.42M | $4.89M | $4.36M | $3.57M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $10.00K | $- | $- | $- | $- | $160.00K | $160.00K | $- | $935.00K | $691.00K | $850.00K | $1.28M | $- | $944.00K | $- | $- |
| Other Non-Current Assets | $944.00K | $943.00K | $936.00K | $920.00K | $885.00K | $888.00K | $882.00K | $849.00K | $883.00K | $864.00K | $842.00K | $851.00K | $843.00K | $823.00K | $840.00K | $817.00K | $809.00K | $632.00K | $608.00K | $531.00K |
| Total Non-Current Assets | $13.30M | $14.68M | $14.43M | $16.02M | $15.15M | $14.40M | $13.75M | $12.85M | $11.96M | $11.27M | $10.44M | $9.55M | $9.75M | $8.77M | $8.37M | $8.16M | $6.23M | $6.46M | $4.96M | $4.10M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0.00B | $-0.00B |
| Total Assets | $26.78M | $27.53M | $25.21M | $25.78M | $23.98M | $24.00M | $24.38M | $24.59M | $23.63M | $21.55M | $20.97M | $20.45M | $20.48M | $18.73M | $17.91M | $16.39M | $14.10M | $13.27M | $11.15M | $10.11M |
| Account Payables | $372.00K | $617.00K | $1.23M | $61.00K | $416.00K | $577.00K | $1.11M | $1.10M | $448.00K | $994.00K | $722.00K | $598.00K | $857.00K | $448.00K | $785.00K | $806.00K | $817.00K | $752.00K | $1.13M | $662.00K |
| Short Term Debt | $1.59M | $1.64M | $1.57M | $1.57M | $1.57M | $1.56M | $1.65M | $1.66M | $1.67M | $1.65M | $1.56M | $1.44M | $1.34M | $1.33M | $1.37M | $1.37M | $1.36M | $1.35M | $1.27M | $1.25M |
| Tax Payables | $- | $564.00K | $- | $- | $- | $4.00K | $- | $- | $- | $200.00K | $- | $- | $- | $771.00K | $- | $- | $- | $553.00K | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $553.00K | $- | $- |
| Other Current Liabilities | $2.73M | $3.58M | $2.11M | $1.65M | $1.36M | $1.80M | $1.57M | $1.89M | $3.22M | $3.19M | $3.04M | $3.26M | $3.97M | $3.94M | $3.63M | $3.47M | $3.21M | $2.05M | $1.78M | $1.84M |
| Total Current Liabilities | $4.69M | $5.83M | $4.91M | $3.28M | $3.34M | $3.94M | $4.33M | $4.65M | $5.34M | $5.83M | $5.32M | $5.30M | $6.18M | $5.72M | $5.79M | $5.64M | $5.38M | $4.71M | $4.18M | $3.75M |
| Long Term Debt | $3.26M | $4.33M | $3.99M | $8.09M | $7.70M | $7.34M | $7.03M | $6.59M | $3.97M | $3.48M | $3.18M | $2.91M | $2.58M | $2.24M | $1.95M | $1.62M | $1.28M | $945.00K | $687.00K | $623.00K |
| Deferred Revenue Non-Current | $-817.00K | $-550.00K | $-495.00K | $-476.00K | $- | $-211.00K | $-211.00K | $-238.00K | $-290.00K | $- | $- | $453.00K | $- | $-1.19M | $- | $- | $-7.00K | $-945.00K | $- | $- |
| Deferred Tax Liabilities Non-Current | $817.00K | $550.00K | $495.00K | $476.00K | $- | $211.00K | $211.00K | $238.00K | $290.00K | $2.15M | $- | $307.00K | $- | $1.49M | $- | $- | $7.00K | $944.00K | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.15M | $- | $-453.00K | $- | $-305.00K | $- | $- | $7.00K | $945.00K | $- | $--0.00B |
| Total Non-Current Liabilities | $4.08M | $4.88M | $4.49M | $8.57M | $7.70M | $7.55M | $7.24M | $6.82M | $4.26M | $3.48M | $3.18M | $3.22M | $2.58M | $2.24M | $1.95M | $1.62M | $1.29M | $1.89M | $687.00K | $623.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0.00B |
| Total Liabilities | $8.76M | $10.71M | $9.40M | $11.85M | $11.04M | $11.49M | $11.57M | $11.47M | $9.61M | $9.31M | $8.51M | $8.51M | $8.76M | $7.96M | $7.74M | $7.26M | $6.67M | $6.60M | $4.87M | $4.37M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K |
| Retained Earnings | $-2.23M | $-3.75M | $-4.91M | $-6.96M | $-8.06M | $-8.61M | $-8.52M | $-8.39M | $-7.65M | $-9.55M | $-9.51M | $-10.24M | $-10.73M | $-11.82M | $-12.60M | $-13.73M | $-15.83M | $-16.77M | $-17.46M | $-18.29M |
| Accumulated Other Comprehensive Income Loss | $-1.70M | $-1.62M | $-1.65M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M |
| Other Total Stockholders Equity | $21.92M | $22.17M | $22.33M | $22.48M | $22.61M | $22.72M | $22.94M | $23.11M | $23.28M | $23.40M | $23.57M | $23.78M | $24.06M | $24.19M | $24.37M | $24.46M | $24.86M | $25.05M | $25.34M | $25.63M |
| Total Stockholders Equity | $18.02M | $16.82M | $15.81M | $13.92M | $12.94M | $12.51M | $12.81M | $13.12M | $14.03M | $12.24M | $12.46M | $11.94M | $11.72M | $10.77M | $10.17M | $9.13M | $7.43M | $6.67M | $6.28M | $5.74M |
| Total Equity | $18.02M | $16.82M | $15.81M | $13.92M | $12.94M | $12.51M | $12.81M | $13.12M | $14.03M | $12.24M | $12.46M | $11.94M | $11.72M | $10.77M | $10.17M | $9.13M | $7.43M | $6.67M | $6.28M | $5.74M |
| Total Liabilities and Stockholders Equity | $26.78M | $27.53M | $25.21M | $25.78M | $23.98M | $24.00M | $24.38M | $24.59M | $23.63M | $21.55M | $20.97M | $20.45M | $20.48M | $18.73M | $17.91M | $16.39M | $14.10M | $13.27M | $11.15M | $10.11M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $26.78M | $27.53M | $25.21M | $25.78M | $23.98M | $24.00M | $24.38M | $24.59M | $23.63M | $21.55M | $20.97M | $20.45M | $20.48M | $18.73M | $17.91M | $16.39M | $14.10M | $13.27M | $11.15M | $10.11M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $4.85M | $5.97M | $5.56M | $9.67M | $9.27M | $8.90M | $8.68M | $8.24M | $5.64M | $5.13M | $4.74M | $4.34M | $3.92M | $3.57M | $3.32M | $2.99M | $2.64M | $2.30M | $1.96M | $1.87M |
| Net Debt | $-1.64M | $-1.32M | $229.00K | $5.99M | $7.46M | $6.07M | $6.49M | $5.59M | $3.68M | $3.13M | $2.61M | $2.56M | $467.00K | $-1.18M | $-1.06M | $541.00K | $1.27M | $334.00K | $539.00K | $434.00K |
Annual Cash Flow Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Net Income | $1.54M | $-3.86M | $-665.00K | $-1.08M | $-4.15M |
| Depreciation and Amortization | $2.91M | $3.63M | $3.69M | $3.32M | $2.67M |
| Deferred Income Tax | $-405.00K | $-339.00K | $-371.00K | $-531.00K | $691.00K |
| Stock Based Compensation | $759.00K | $563.00K | $743.00K | $872.00K | $908.00K |
| Change in Working Capital | $-534.00K | $-4.17M | $-802.00K | $2.32M | $-1.73M |
| Accounts Receivables | $1.05M | $424.00K | $-760.00K | $377.00K | $373.00K |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-494.00K | $-281.00K | $417.00K | $-546.00K | $304.00K |
| Other Working Capital | $-1.09M | $-4.31M | $-459.00K | $2.49M | $-2.40M |
| Other Non Cash Items | $33.00K | $94.00K | $-2.18M | $5.33M | $131.00K |
| Net Cash Provided by Operating Activities | $4.31M | $-4.08M | $414.00K | $4.89M | $-1.48M |
| Investments in Property Plant and Equipment | $-1.73M | $-991.00K | $-182.00K | $-187.00K | $-159.00K |
| Acquisitions Net | $- | $140.00K | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $3.81M | $- | $- | $- | $- |
| Other Investing Activities | $3.75M | $-7.00K | $-38.00K | $-21.00K | $-2.00K |
| Net Cash Used for Investing Activities | $2.08M | $-858.00K | $-220.00K | $-208.00K | $-159.00K |
| Debt Repayment | $-415.00K | $-678.00K | $-688.00K | $-664.00K | $-294.00K |
| Common Stock Issued | $-33.00K | $-9.00K | $72.00K | $- | $- |
| Common Stock Repurchased | $-33.00K | $-9.00K | $-72.00K | $-78.00K | $-54.00K |
| Dividends Paid | $-3.97M | $-993.00K | $-279.00K | $-1.19M | $-799.00K |
| Other Financing Activities | $1.45M | $2.19M | $-68.00K | $4.00K | $-54.00K |
| Net Cash Used Provided by Financing Activities | $-3.00M | $501.00K | $-1.03M | $-1.92M | $-1.15M |
| Effect of Forex Changes on Cash | $-170.00K | $-10.00K | $- | $- | $- |
| Net Change in Cash | $3.21M | $-4.45M | $-841.00K | $2.76M | $-2.79M |
| Cash at End of Period | $7.28M | $2.83M | $1.99M | $4.75M | $1.96M |
| Cash at Beginning of Period | $4.07M | $7.28M | $2.83M | $1.99M | $4.75M |
| Operating Cash Flow | $4.31M | $-4.08M | $414.00K | $4.89M | $-1.48M |
| Capital Expenditure | $-1.73M | $-991.00K | $-182.00K | $-187.00K | $-159.00K |
| Free Cash Flow | $2.58M | $-5.07M | $232.00K | $4.70M | $-1.64M |
Quarterly Cash Flow Statement
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $677.00K | $-530.00K | $-159.00K | $-2.05M | $-1.11M | $-543.00K | $83.00K | $134.00K | $739.00K | $-1.62M | $39.00K | $-338.00K | $-97.00K | $-688.00K | $-384.00K | $-726.00K | $-2.10M | $-945.00K | $-688.00K | $-827.00K |
| Depreciation and Amortization | $718.00K | $695.00K | $874.00K | $907.00K | $927.00K | $918.00K | $911.00K | $912.00K | $1.01M | $859.00K | $860.00K | $867.00K | $827.00K | $762.00K | $714.00K | $696.00K | $685.00K | $575.00K | $551.00K | $664.00K |
| Deferred Income Tax | $-80.00K | $-267.00K | $-55.00K | $-19.00K | $-486.00K | $221.00K | $- | $27.00K | $52.00K | $-450.00K | $- | $467.00K | $-1.24M | $244.00K | $-159.00K | $-593.00K | $1.29M | $-7.00K | $- | $- |
| Stock Based Compensation | $190.00K | $250.00K | $163.00K | $160.00K | $126.00K | $114.00K | $217.00K | $169.00K | $178.00K | $179.00K | $179.00K | $238.00K | $277.00K | $178.00K | $177.00K | $143.00K | $401.00K | $187.00K | $297.00K | $287.00K |
| Change in Working Capital | $167.00K | $802.00K | $-1.33M | $-2.31M | $-954.00K | $430.00K | $-1.62M | $-592.00K | $-184.00K | $1.60M | $-733.00K | $-917.00K | $2.57M | $1.40M | $-732.00K | $-479.00K | $-1.24M | $721.00K | $-633.00K | $-4.00K |
| Accounts Receivables | $-645.00K | $1.39M | $222.00K | $998.00K | $-1.33M | $534.00K | $-664.00K | $49.00K | $-710.00K | $565.00K | $-588.00K | $299.00K | $-548.00K | $1.21M | $-319.00K | $57.00K | $-595.00K | $1.27M | $-191.00K | $822.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $93.00K | $-159.00K | $570.00K | $-1.13M | $352.00K | $-77.00K | $525.00K | $-2.00K | $-652.00K | $546.00K | $-272.00K | $-124.00K | $259.00K | $-409.00K | $337.00K | $21.00K | $11.00K | $-65.00K | $379.00K | $-469.00K |
| Other Working Capital | $719.00K | $-430.00K | $-2.12M | $-2.19M | $24.00K | $-27.00K | $-1.49M | $-639.00K | $1.18M | $487.00K | $127.00K | $-1.09M | $2.86M | $593.00K | $-750.00K | $-557.00K | $-652.00K | $-487.00K | $-821.00K | $-357.00K |
| Other Non Cash Items | $-1.00K | $-2.00K | $94.00K | $-2.48M | $1.41M | $-1.51M | $2.20M | $1.97M | $-2.18M | $1.20M | $2.74M | $2.12M | $38.00K | $433.00K | $159.00K | $1.46M | $2.73M | $131.00K | $1.21M | $1.26M |
| Net Cash Provided by Operating Activities | $1.67M | $948.00K | $-413.00K | $-3.32M | $-1.49M | $1.14M | $-413.00K | $650.00K | $-388.00K | $565.00K | $345.00K | $317.00K | $2.33M | $1.89M | $-225.00K | $-959.00K | $-958.00K | $662.00K | $-473.00K | $120.00K |
| Investments in Property Plant and Equipment | $-765.00K | $-612.00K | $-466.00K | $-344.00K | $-254.00K | $-111.00K | $-50.00K | $-34.00K | $-68.00K | $-30.00K | $-43.00K | $-29.00K | $-91.00K | $-24.00K | $-41.00K | $-56.00K | $-35.00K | $5.00K | $-8.00K | $-39.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $3.81M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-61.00K | $-3.76M | $133.00K | $-70.00K | $17.00K | $167.00K | $-9.00K | $17.00K | $-50.00K | $4.00K | $7.00K | $-25.00K | $-7.00K | $4.00K | $-32.00K | $8.00K | $-8.00K | $30.00K | $13.00K | $66.00K |
| Net Cash Used for Investing Activities | $-826.00K | $-565.00K | $-333.00K | $-344.00K | $-237.00K | $56.00K | $-59.00K | $-17.00K | $-118.00K | $-26.00K | $-36.00K | $-54.00K | $-98.00K | $-20.00K | $-73.00K | $-48.00K | $-43.00K | $5.00K | $5.00K | $27.00K |
| Debt Repayment | $-105.00K | $-103.00K | $-169.00K | $-169.00K | $-169.00K | $-171.00K | $-171.00K | $-172.00K | $-172.00K | $-173.00K | $-174.00K | $-175.00K | $-174.00K | $-141.00K | $-72.00K | $-74.00K | $-74.00K | $-74.00K | $-75.00K | $-134.00K |
| Common Stock Issued | $- | $- | $- | $- | $- | $-9.00K | $- | $- | $- | $-5.00K | $- | $- | $4.00K | $-4.00K | $- | $-55.00K | $55.00K | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $-8.00K | $- | $-1.00K | $- | $- | $-5.00K | $5.00K | $- | $-32.00K | $- | $-46.00K | $- | $-55.00K | $- | $1.00K | $- | $- |
| Dividends Paid | $-993.00K | $-992.00K | $-993.00K | $- | $- | $-335.00K | $- | $- | $- | $-279.00K | $- | $-393.00K | $-394.00K | $-399.00K | $- | $-799.00K | $- | $-799.00K | $- | $- |
| Other Financing Activities | $- | $1.42M | $-169.00K | $2.17M | $- | $344.00K | $-171.00K | $- | $-5.00K | $-63.00K | $-174.00K | $-32.00K | $-4.00K | $4.00K | $- | $- | $-55.00K | $1.00K | $-75.00K | $- |
| Net Cash Used Provided by Financing Activities | $-1.10M | $321.00K | $-1.16M | $2.00M | $-169.00K | $-172.00K | $-171.00K | $-172.00K | $-177.00K | $-515.00K | $-174.00K | $-600.00K | $-568.00K | $-582.00K | $-72.00K | $-928.00K | $-74.00K | $-73.00K | $-75.00K | $-134.00K |
| Effect of Forex Changes on Cash | $-352.00K | $87.00K | $-44.00K | $-3.00K | $37.00K | $10.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-605.00K | $791.00K | $-1.95M | $-1.66M | $-1.86M | $1.02M | $-643.00K | $461.00K | $-683.00K | $24.00K | $135.00K | $-337.00K | $1.67M | $1.29M | $-370.00K | $-1.94M | $-1.07M | $594.00K | $-543.00K | $13.00K |
| Cash at End of Period | $6.49M | $7.28M | $5.33M | $3.67M | $1.81M | $2.83M | $2.19M | $2.65M | $1.97M | $1.99M | $2.13M | $1.79M | $3.46M | $4.75M | $4.38M | $2.44M | $1.37M | $1.96M | $1.42M | $1.43M |
| Cash at Beginning of Period | $7.10M | $6.49M | $7.28M | $5.33M | $3.67M | $1.81M | $2.83M | $2.19M | $2.65M | $1.97M | $1.99M | $2.13M | $1.79M | $3.46M | $4.75M | $4.38M | $2.44M | $1.37M | $1.96M | $1.42M |
| Operating Cash Flow | $1.67M | $948.00K | $-413.00K | $-3.32M | $-1.49M | $1.14M | $-413.00K | $650.00K | $-388.00K | $565.00K | $345.00K | $317.00K | $2.33M | $1.89M | $-225.00K | $-959.00K | $-958.00K | $662.00K | $-473.00K | $120.00K |
| Capital Expenditure | $-765.00K | $-612.00K | $-466.00K | $-344.00K | $-254.00K | $-111.00K | $-50.00K | $-34.00K | $-68.00K | $-30.00K | $-43.00K | $-29.00K | $-91.00K | $-24.00K | $-41.00K | $-56.00K | $-35.00K | $5.00K | $-8.00K | $-39.00K |
| Free Cash Flow | $906.00K | $336.00K | $-879.00K | $-3.66M | $-1.75M | $1.03M | $-463.00K | $616.00K | $-456.00K | $535.00K | $302.00K | $288.00K | $2.24M | $1.87M | $-266.00K | $-1.01M | $-993.00K | $667.00K | $-481.00K | $81.00K |
Psychemedics Dividends
Understand Psychemedics's dividend history, dividend yield, payout ratio, and more.
Dividend Yield
4.70%
Dividend Payout Ratio
-19.23%
Dividend Paid & Capex Coverage Ratio
-2.31x
Psychemedics Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.07 | $0.07 | May 24, 2023 | May 25, 2023 | June 08, 2023 | May 09, 2023 |
| $0.07 | $0.07 | March 30, 2023 | March 31, 2023 | April 10, 2023 | March 21, 2023 |
| $0.07 | $0.07 | December 01, 2022 | December 02, 2022 | December 16, 2022 | November 09, 2022 |
| $0.07 | $0.07 | August 23, 2022 | August 24, 2022 | September 09, 2022 | August 09, 2022 |
| $0.07 | $0.07 | May 26, 2022 | May 27, 2022 | June 24, 2022 | May 10, 2022 |
| $0.05 | $0.05 | December 17, 2021 | December 20, 2021 | December 30, 2021 | December 10, 2021 |
| $0.18 | $0.18 | February 20, 2020 | February 21, 2020 | March 03, 2020 | February 11, 2020 |
| $0.18 | $0.18 | November 04, 2019 | November 05, 2019 | November 15, 2019 | October 22, 2019 |
| $0.18 | $0.18 | August 05, 2019 | August 06, 2019 | August 16, 2019 | July 23, 2019 |
| $0.18 | $0.18 | May 06, 2019 | May 07, 2019 | May 17, 2019 | April 23, 2019 |
| $0.18 | $0.18 | March 13, 2019 | March 14, 2019 | March 25, 2019 | March 04, 2019 |
| $0.18 | $0.18 | November 01, 2018 | November 02, 2018 | November 12, 2018 | October 23, 2018 |
| $0.18 | $0.18 | August 06, 2018 | August 07, 2018 | August 17, 2018 | July 24, 2018 |
| $0.18 | $0.18 | May 07, 2018 | May 08, 2018 | May 18, 2018 | April 24, 2018 |
| $0.15 | $0.15 | March 16, 2018 | March 19, 2018 | March 29, 2018 | March 07, 2018 |
| $0.15 | $0.15 | November 03, 2017 | November 06, 2017 | November 17, 2017 | October 24, 2017 |
| $0.15 | $0.15 | August 10, 2017 | August 14, 2017 | August 24, 2017 | August 03, 2017 |
| $0.15 | $0.15 | May 04, 2017 | May 08, 2017 | May 18, 2017 | April 26, 2017 |
| $0.15 | $0.15 | February 14, 2017 | February 16, 2017 | February 27, 2017 | February 06, 2017 |
| $0.15 | $0.15 | November 03, 2016 | November 07, 2016 | November 17, 2016 | October 27, 2016 |
Valuation
Analyze the market cap, enterprise value, and valuation metrics for Psychemedics.
Market Cap & Enterprise Value
Market Cap: $13.45M
Enterprise Value: $17.32M
Valuation Ratios
P/E Ratio: -4.09
P/B Ratio: 2.55
P/CF Ratio: -11.48
Valuation Multiples
E/V to Sales: 0.78
E/V to EBITDA: -69.02
Market Cap & Enterprise Value
Market capitalization and enterprise value provide an understanding of a company's market value and total value, respectively.
- Market Cap: The total market value of a company's outstanding shares of stock. It represents the company's equity value and is calculated by multiplying the current share price by the total number of outstanding shares.
- Enterprise Value (EV): A measure of a company's total value, often seen as a more comprehensive alternative to equity market capitalization. It includes market cap plus debt, minority interest, and preferred shares, minus total cash and cash equivalents.
Valuation Ratios
Valuation ratios are used to evaluate the value of a company compared to its earnings, book value, and cash flow.
- P/E Ratio: Price to Earnings Ratio, indicating how much investors are willing to pay for a dollar of earnings.
- P/B Ratio: Price to Book Ratio, comparing the company's market value to its book value. A lower ratio may indicate undervaluation.
- P/CF Ratio: Price to Cash Flow Ratio, evaluating the market value relative to the operating cash flow. A lower ratio can signal a more attractive investment.
Valuation Multiples
Valuation multiples help assess a company's value relative to its revenue and earnings.
- EV to Sales: Enterprise Value to Sales, comparing the enterprise value to sales revenue. A lower ratio can indicate a more attractive investment.
- EV to EBITDA: Enterprise Value to EBITDA, comparing the enterprise value to earnings before interest, taxes, depreciation, and amortization. A lower ratio suggests a company may be undervalued.
Psychemedics Growth
View income_statement_chart2_annual_data financial growth metrics for Psychemedics, including income statement, balance sheet, and cash flow growth.
Income Growth
Revenue Growth: -11.74%
Operating Income Growth: -58.55%
Cash Flow Growth
Net Income Growth: -20.20%
Free Cash Flow Growth: 116.84%
Balance Sheet Growth
Total Assets Growth: -9.32%
Total Liabilities Growth: -10.24%
Income Growth
This section highlights key metrics related to income growth, showing how the company’s revenue and operating income have changed over time:
- Revenue Growth: The increase in a company's sales over time. It is a measure of how quickly the company is growing its revenue. This chart shows the historical trend of revenue growth.
- Operating Income Growth: The growth rate of a company's operating income, which is the income earned from its normal business operations. This chart helps to assess the company's operational efficiency and profitability growth over time.
Cash Flow Growth
This section highlights key metrics on the company's cash flow growth, reflecting changes in net income and free cash flow over time.
- Net Income Growth: The increase in a company's net profit over time. It reflects the company's ability to increase its profitability. This chart provides insight into how the company's bottom line has grown.
- Free Cash Flow Growth: The growth in a company's free cash flow, which is the cash generated by the company after accounting for capital expenditures. This chart is important for understanding the company's financial flexibility and ability to fund operations and growth.
Balance Sheet Growth
This section highlight key metrics related to balance sheet growth, which indicate how the company’s total assets and liabilities have changed over time:
- Total Assets Growth: The rate at which a company's total assets are increasing over time. This chart indicates how the company's asset base is expanding, which can be a sign of growth and investment in future operations.
- Total Liabilities Growth: The rate at which a company's total liabilities are increasing over time. This chart helps to assess the company's financial leverage and risk over time.
Peers: Medical - Diagnostics & Research
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
FONAR Corporation
FONR
|
$102.52M | $16.20 | $1.66 | $9.70 | $0.62 |
Burning Rock Biotech Limited
BNR
|
$38.01M | $3.71 | $-6.38 | $-10.77 | $9.16 |
Sera Prognostics, Inc.
SERA
|
$233.61M | $7.21 | $-1.16 | $-5.15 | $2.66 |
Olink Holding AB (publ)
OLK
|
$3.24B | $26.08 | $-0.26 | $-98.51 | $6.20 |
LumiraDx Limited
LMDX
|
$- | $0.02 | $-1.59 | $-0.56 | $-2.27 |
Genetron Holdings Limited
GTH
|
$127.29M | $4.03 | $-9.53 | $-2.43 | $3.94 |
DarioHealth Corp.
DRIO
|
$33.93M | $1.13 | $-1.93 | $-0.89 | $0.84 |
Neuronetics, Inc.
STIM
|
$25.75M | $0.85 | $-1.05 | $-2.75 | $2.43 |
Castle Biosciences, Inc.
CSTL
|
$814.08M | $29.35 | $-2.14 | $-10.06 | $1.48 |
Exagen Inc.
XGN
|
$52.16M | $3.00 | $-1.34 | $-1.49 | $1.55 |
Sotera Health Company
SHC
|
$4.47B | $15.80 | $0.18 | $92.16 | $10.67 |
More metrics for Psychemedics
Access more key metrics, financials, ratios, and more with the links below.